Developing Innovative High-Impact Therapeutic Solutions that Address Major Unmet Needs in Healthcare

We are building a multi-asset pipeline of products with late-state lead indications and follow-on indications that represent significant areas of unmet need.

Learn More

Orchestra BioMed^™ is a Healthcare Innovation Company

Orchestra BioMed^™ is a biomedical innovation company focused on developing high-impact therapeutic solutions to address significant unmet needs in cardiovascular health and other areas. We specialize in developing novel therapies that are:

Designed to fit current clinical treatment paradigms and leverage the established procedural techniques well-known to interventional physicians; and
Based on the use as well as convergence of advanced medical technology, biopharmaceuticals, biomaterials-based drug delivery, and intelligent bioelectronic therapeutic algorithms

Our business model is designed to advance promising therapeutic solutions through development and aims to leverage strategic partnerships with established global commercial leaders to optimize commercialization and profitability. The Orchestra BioMed^™ team of industry leaders has proven expertise in every phase of medtech and biopharma product development. Our primary focus on cardiovascular disease reflects our goal to rapidly advance disruptive solutions that will improve the standard of care for millions of patients worldwide.

Product Pipeline Overview

Advancing a deep, multi-asset pipeline of high-impact therapeutic solutions built around two technology platforms.

Learn More

Transformational Therapies for Artery Disease & Hypertension

Innovative therapies that target large unmet healthcare needs

BackBeat CNT

Patented, intelligent bioelectronic treatment for hypertension

Virtue^® SEB

First-in-class drug-eluting balloon angioplasty system for treatment of coronary artery disease

News & Events

Orchestra BioMed^TM Secures $20 Million Financing Facility from Silicon Valley Bank

December 10, 2019

New York, NY – Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine, today announced that it has entered into a $20 million credit facility agreement with Silicon Valley Bank (SVB), the bank of the world’s most innovative companies and their investors. This agreement provides up to $20 million of new capital to the Company for development and general corporate purposes, with an initial up to $10 million draw available at Orchestra BioMed’s sole option during the next 12 months and the remainder available to the Company following the completion of certain milestones.

Orchestra BioMed™ to Present at the Innovation in Cardiovascular Interventions Meeting and the CSI Focus D-HF Congress

December 5, 2019

New Hope, PA – Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine, today announced upcoming presentations at the Innovation in Cardiovascular Interventions (ICI) Meeting in Tel-Aviv, Israel, taking place December 8-10, 2019 and the CSI Focus D-HF Congress in Paris taking place December 13-14, 2019.

Read All News